FDA Filing for UniQure, CSL's Haemophilia B Gene Therapy Planned for Early 2022

FDA Filing for UniQure, CSL's Haemophilia B Gene Therapy Planned for Early 2022

FirstWord Pharma

Image

Please enable the javascript to submit this form

Supported by educational grants from Bayer, BioMarin, CSL Behring, Freeline Therapeutics Limited, Pfizer Inc., Spark Therapeutics, and uniQure, Inc.

Essential SSL